Literature DB >> 17531955

The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation.

Naibedya Chattopadhyay1, Stephen J Quinn, Olga Kifor, Chianping Ye, Edward M Brown.   

Abstract

Strontium ranelate has several beneficial effects on bone and reduces the risk of vertebral and hip fractures in women with postmenopausal osteoporosis. We investigated whether Sr(2+) acts via a cell surface calcium-sensing receptor (CaR) in HEK293 cells stably transfected with the bovine CaR (HEK-CaR) and rat primary osteoblasts (POBs) expressing the CaR endogenously. Elevating Ca(o)(2+) or Sr(2+) concentration-dependently activated the CaR in HEK-CaR but not in non-transfected cells, but the potency of Sr(2+) varied depending on the biological response tested. Sr(2+) was less potent than Ca(o)(2+) in stimulating inositol phosphate accumulation and in increasing Ca(i)(2+), but was comparable to Ca(o)(2+) in stimulating ERK phosphorylation and a non-selective cation channel, suggesting that Ca(2+) and Sr(2+) have differential effects on specific cellular processes. With physiological concentrations of Ca(o)(2+), Sr(2+)-induced further CaR activation. Neither Sr(2+) nor Ca(o)(2+) affected the four parameters just described in non-transfected cells. In POB, Sr(2+) stimulated cellular proliferation. This effect was CaR-mediated, as transfecting the cells with a dominant negative bovine CaR significantly attenuated Ca(o)(2+)-stimulated POB proliferation. Finally, Sr(2+) significantly increased the mRNA levels of the immediate early genes, c-fos and egr-1, which are involved in POB proliferation, and this effect was attenuated by overexpressing the dominant negative CaR. In conclusion, Sr(2+) is a full CaR agonist in HEK-CaR and POB, and, therefore, the anabolic effect of Sr(2+) on bone in vivo could be mediated, in part, by the CaR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531955     DOI: 10.1016/j.bcp.2007.04.020

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  61 in total

1.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Authors:  J A Kanis; H Johansson; A Oden; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-02-02       Impact factor: 4.507

Review 2.  The calcium-sensing receptor in bone.

Authors:  Toru Yamaguchi
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

3.  Effects on growth and osteogenic differentiation of mesenchymal stem cells by the strontium-added sol-gel hydroxyapatite gel materials.

Authors:  Maria Grazia Raucci; Daniela Giugliano; M A Alvarez-Perez; Luigi Ambrosio
Journal:  J Mater Sci Mater Med       Date:  2015-02-04       Impact factor: 3.896

4.  The in vitro and in vivo performance of a strontium-containing coating on the low-modulus Ti35Nb2Ta3Zr alloy formed by micro-arc oxidation.

Authors:  Wei Liu; Mengqi Cheng; Tuerhongjiang Wahafu; Yaochao Zhao; Hui Qin; Jiaxing Wang; Xianlong Zhang; Liqiang Wang
Journal:  J Mater Sci Mater Med       Date:  2015-07-08       Impact factor: 3.896

5.  Osteoblasts play key roles in the mechanisms of action of strontium ranelate.

Authors:  T C Brennan; M S Rybchyn; W Green; S Atwa; A D Conigrave; R S Mason
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

6.  An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts.

Authors:  Mark S Rybchyn; Michael Slater; Arthur D Conigrave; Rebecca S Mason
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

7.  Strontium: friend or foe of bone formation?

Authors:  H Xie; Q Ye
Journal:  Osteoporos Int       Date:  2015-04-15       Impact factor: 4.507

8.  Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal.

Authors:  Roberto Cesareo; Clemente Napolitano; Mario Iozzino
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.

Authors:  René Rizzoli; Michel Laroche; Marc-Antoine Krieg; Isolde Frieling; Thierry Thomas; Pierre Delmas; Dieter Felsenberg
Journal:  Rheumatol Int       Date:  2010-05-29       Impact factor: 2.631

10.  Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.

Authors:  P J Meunier; C Roux; S Ortolani; M Diaz-Curiel; J Compston; P Marquis; C Cormier; G Isaia; J Badurski; J D Wark; J Collette; J Y Reginster
Journal:  Osteoporos Int       Date:  2009-01-20       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.